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POPULAR SCIENCE SUMMARY OF THE THESIS 
 
This thesis has proved that a new examination method called 99mTc-Sestamibi SPECT/CT can 
help to determine if a kidney tumour is benign or malignant, all without having the patient to 
go under the knife. Nowadays, the only option to distinguish benign from malignant kidney 
tumours is either biopsy or operation. To improve the diagnostic accuracy of the above-
mentioned examination method, we also propose that kidney tumours showing increased 
uptake of 99mTc-Sestamibi should be biopsied and followed by a detailed histological analysis 
due to their possible benign nature. On the other hand, kidney tumours with decreased uptake 
of 99mTc-Sestamibi should be operated since most probably those tumours are malignant. The 
main benefit of the proposed imaging strategy will be avoiding unnecessary surgery for 






























Purpose: An increasing body of literature indicates the beneficial role of 99mTc-Sestamibi 
SPECT/CT in the non-invasive differentiation of renal oncocytoma (RO) from renal cell 
carcinoma (RCC). This thesis presents a comprehensive approach of 99mTc-Sestamibi 
SPECT/CT examination following the implementation of quantitative tools in addition to 
visual assessment. An additional aim is to explain the differences in 99mTc-Sestamibi uptake 
among the different RCC subgroups on histometabolomic grounds. 
Methods: 57 radiologically detected kidney tumours from 52 patients were included in the 
present thesis. Each participant underwent a 99mTc-Sestamibi SPECT/CT examination before 
nephrectomy or percutaneous kidney biopsy. Kidney tumours with increased 99mTc-Sestamibi 
uptake were classified as positive (Sestamibi positive). In contrast, those with equal or 
decreased 99mTc-Sestamibi compared to the ipsilateral non-tumoral kidney parenchyma were 
classified as negative (Sestamibi negative). Following the visual assessment, quantitative 
SUVmean and SUVmax measurements performed in the examined kidney tumour and the non-
tumoral kidney parenchyma that correlated with the histopathological results. Additional 
immunohistochemical investigation, in situ metabolomics profile characterisation and 
correlation of mitochondrial content with 99mTc-Sestamibi SPECT/CT data, were also 
performed. 
Results: Visual assessment of 99mTc-Sestamibi SPECT/CT examination resulted in a 
sensitivity of 82% whereas, the quantitative assessment showed a sensitivity of 64% 
regarding the preoperative characterisation of RO. 99mTc-Sestamibi SPECT/CT identifies a 
larger Sestamibi-positive tumour group containing RO, hybrid oncocytic chromophobe 
tumour (HOCT) and the majority of chromophobe RCC (chRCC). A discriminatory 
metabolomic signature was identified for Sestamibi positive Birt-Hogg-Dubè-associated 
HOCT vs other renal oncocytic tumours. Metabolomic differences were also found between 
Sestamibi positive and negative chRCCs. 
Conclusion: Sestamibi positive kidney tumours on SPECT/CT examination are possibly of 
benign nature. Quantitative assessment with SUV SPECT measurements did not improve the 
diagnostic performance of 99mTc-Sestamibi SPECT/CT. Sestamibi negative kidney tumours 
should be considered for surgery due to their possibly malignant nature. On the other hand, 
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1 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Epidemiology of renal neoplasia 
Kidney cancer accounts for almost 5% of all the new cancer cases diagnosed annually [1]. 
The most common histological type of kidney cancer arising from renal tubular epithelium 
with a prevalence of 75% among all primary kidney cancers is the renal cell carcinoma 
(RCC) [2]. RCC contributes to 5% of all cancers in the male, and 3% of all cancers in the 
female population [3] with hereditary predisposition accounting for approximately 5% of all 
RCC cases [4]. Despite the gradual increase of RCC incidence, stabilisation of the mortality 
rates has been observed mainly in developed countries but not in developing countries [5]. 
The incidence of RCC may vary universally, but the regions of the highest rates are observed 
in the Czech Republic, Eastern-North Europe, Australia, and North America [3,6]. According 
to the latest data reports (2018) from the World Health Organization (WHO), RCC ranks in 
the 13th position of cancer-related deaths worldwide [3]. 
 
1.2 RCC subtypes 
The three main RCC subcategories include clear cell RCC (ccRCC), papillary RCC (pRCC) 
types 1-2 and chromophobe RCC (chRCC), accounting for 70%-80%, 14%–17% and 4%–
8% of cases respectively [7]. The metastatic rate of the RCC subtypes above is highest for 
ccRCC (8,7%) followed by pRCC (5,5%) and then chRCC (2,9%) [8]. Other malignant 
tumours of the kidney apart from RCC, are transitional cell carcinoma (urothelial carcinoma 
of the renal pelvis) and nephroblastoma in children (Wilms tumour) [2,7].  
The dynamic nature of scientific advances leads to a continuous re-evaluation of RCC, as 
reflected in the recent edition (2016) of the WHO classification of urogenital neoplasia [9]. 
The latest re-examination of RCC from the WHO led to the recognition of 12 RCC subtypes 
and the emerge of other RCC entities [10]. A worth mentioned example of a newly 
recognised separate RCC entity is clear cell papillary RCC, a tumour of good prognosis 
previously described in patients of chronic kidney disease [9,10]. Hybrid chromophobe 
oncocytic tumour (HOCT) which is still a subtype of chRCC on the most recent WHO 
classification, emerges nowadays as a distinct clinicopathological entity on molecular 
grounds [11]. Another example of an emerging renal tumour seeking recognition as a 
separate entity is low grade oncocytic renal tumour (LOT), which is a tumour of overlapping 
morphology with renal oncocytoma (RO) and eosinophilic chRCC [12].  
 
1.3 Benign renal neoplasia 
RO derives from the distal tubular renal epithelium [13], exhibits eosinophilia due to its 
abundance in mitochondria [14] and constitutes almost 5% of all renal epithelial neoplasms, 
data based on surgical specimens [15,16]. As the second benign renal tumour category after 
angiomyolipoma (AML), RO was considered a malignant entity for almost 35 years since its 
first description in the early ’40s [17]. Both RO and AML contribute to 10% of unnecessary 
nephrectomies since they share common imaging characteristics with RCC [16,18] (Fig.1). 
Simple renal cysts are also benign while complicated renal cysts classified according to 




Figure 1. Two different patients, two different renal tumours (arrows) incidentally 
discovered. Contrast-enhanced axial CT scans of the abdomen exhibiting small tumours on 
the right kidney. Both tumours share common imaging characteristics which makes an 
accurate preoperative diagnosis difficult. The tumour on the left (a) turned out to be RCC of 
clear cell subtype while the tumour on the right (b) was postoperatively diagnosed as a benign 
RO. (Karolinska University Hospital Huddinge, MIDOR study) 
 
1.4 Symptoms of renal neoplasia 
The widespread use of different abdominal imaging techniques leads to increased incidental 
detection of renal tumours. The old classic triad of symptoms, namely flank pain, 
macrohematuria and a palpable mass in the abdomen indicates nowadays a relatively 
advanced disease often followed by paraneoplastic symptoms [20].  
 
1.5 Imaging of renal neoplasia 
Since no reliable serum or urine biomarkers for kidney cancer exist despite recent advances 
[21,22], imaging plays a unique role in its detection and characterisation [23]. Ultrasound 
(US), contrast-enhanced ultrasound (CEUS), contrast-enhanced computed tomography 
(CECT), perfusion computed tomography (CTp), magnetic resonance imaging (MRI), 
positron emission tomography/computed tomography (PET/CT) and recently single-photon 
computed tomography/computed tomography (SPECT/CT) are preoperative diagnostic tools 
used to detect, characterise and stage renal neoplasia [18,24]. The accurate non-invasive 
characterisation of solid renal tumours still raises diagnostic difficulties due to shared, non-
pathognomonic imaging characteristics between benign and malignant counterparts [25].  
1.5.1 CT and MRI 
CT and MRI can easily detect and characterise a fat-rich AML, but accurate diagnosis can be 
challenging when fat-poor or fat-invisible AML are encountered [26].  Similar diagnostic 
challenges set the absence or presence of a stellate scar in a solid renal tumour since it is 
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found in only up to 33% of RO [27].  At the same time, central scars (Fig.2) and intravenous 
contrast uptake with subsequent washout seen on a multiphase CECT (Fig.3) are 
characteristics not only of RO but also of RCC [28].  
 
Figure 2:  Contrast-enhanced axial (a) and coronal (b) CT plans in the nephrographic phase 
with a renal oncocytoma on the left kidney exhibiting a subtle central scar.  Only 1/3 of renal 
oncocytomas display central scar, which makes a definite diagnosis difficult since RCC can 




Figure 3: Multiphasic contrast-enhanced axial CT scan of the abdomen exhibiting a small 
renal oncocytoma on the right kidney. Renal tumour of solid character on the native phase (a) 
shows contrast uptake (b) on the corticomedullary phase with subsequent washout (c, d) on 
later nephrographic and excretory phases. Contrast uptake and washout is common imaging 
characteristic for renal oncocytomas and RCCs. (Karolinska University Hospital Huddinge, 
MIDOR study) 
 
Advances in radiomics using texture analysis on unenhanced or CECT images report 
promising results concerning the detection of fat-poor AML, the characterisation of RCC 
subtypes and even the differentiation of RO from chRCC [29–31]. Concerning the value of 
MRI in imaging renal neoplasia (Fig.4), a recent meta-analysis from Tordjman et al. stands 
out that apparent diffusion coefficient (ADC) values measured on solid tumour components 
can differentiate ccRCC from other tumour types exhibiting sensitivity and specificity of 80% 




Figure 4: RCC of papillary subtype (arrow) with small calcifications (a) on the native 
coronal CT scan. The nephrographic phase reveals enhancement of septa (b, d) on the axial 
CT scan and the T1 weighted MRI axial MRI sequence, respectively. T2 weighted coronal 
MRI sequence of the upper abdomen (c) in the same patient reveals the non-cystic nature of 
the renal tumour. (Karolinska University Hospital Huddinge, MIDOR study) 
 
1.5.2 CEUS and FDG PET/CT 
Conventional US followed by CEUS can successfully differentiate cystic from solid tumour 
components as well as the presence of renal pseudotumor since the latter follows the same 
contrast uptake pattern as renal parenchyma. Still, its usage in solid renal tumour 
differentiation is limited [33] (Fig.5). The use of PET/CT having 18F-fluorodeoxyglucose 
(FDG) as a radiotracer in the recognition and characterisation of renal neoplasia is also 
limited mainly due to the FDG excretion from the kidney that results in a high background 
activity within this organ [34,35]. Furthermore, other innovative radiotracers did not succeed 




Figure 5: (a) Grey-scale ultrasonography shows a hypoechoic cortical lesion in the medial 
aspect of the right kidney. CEUS obtained during the cortical (b) and parenchymal (c,d) 
phase reveals slow enhancement of the lesion which remains hypoenhancing to surrounding 
normal renal parenchyma. The lesion has the same attenuation as the adjacent renal 
parenchyma on unenhanced CT (e) and displays progressive enhancement on 
corticomedullary(f) and nephrographic(g) phase. (The above-described kidney tumour 
turned out to be a HOCT.) 
(Figure and Figure legend courtesy of BJR|case reports: Georgios Kalarakis, Katharina 
Brehmer, Anders Svensson, Rimma Axelsson, Torkel B Brismar, Antonios Tzortzakakis. 
Combining contrast-enhanced ultrasound, CT perfusion and 99mTc-Sestamibi SPECT/CT to 
guide diagnosis in a case of solid renal tumour. BJR|case reports. September 2020) 
 
1.5.3 CTp 
The principle of kidney CTp technique is based on the depiction of renal tumour perfusion 
and its vascular permeability with the acquisition of multiple contrast-enhanced CT scans 
[37]. CTp parameters (blood volume: BV, blood flow: BF, permeability surface: PS and mean 
transit time: MTT) for the non-tumoral renal cortex and the solid renal tumour are evaluated 
[38–42]. Differences in perfusion parameters between non-tumoral renal cortex and solid 
renal lesions have been reported in RCC and among the different RCC categories (Fig.6a-f).  
On the contrary, no differences detected in any of the CTp parameters between RO and non-
tumoral renal cortex. To exemplify, Mazzei et al. reported that “the accuracy, sensitivity, and 
specificity to predict RCC were 95.92%, 100%, and 66.7%, respectively, for CTp whereas 
they were 89.80%, 93.35%, and 50%, respectively, for multiphasic CT” [38]. One of the 
main limitations of the CTp is the high radiation dose to the patient that restricts the clinical 
experience on this examination technique despite the low intravenous contrast dose given. As 
a result, this examination method lacks standardisation, external validation and few published 




Figure 6: (a-f) A VOI including the suspect lesion (1) and part of the renal cortex (3) was 
manually defined in order to calculate the tissue attenuation curve and mean perfusion 
values. The lesion exhibited lower BF and BV than the renal cortex. On 99mTc-Sestamibi 
SPECT/CT (g-h), the lesion demonstrated clear focal uptake relative to surrounding renal 
parenchyma, indicating its possible benign character. 
MIP; Maximum Intensity Projection, BF; Blood Flow, BV; Blood Volume, MTT; Meant 
Transit Time, TTP; Time to Peak, Tmax; Time to Maximum; FEP; flow extraction product, 
VOI; Volume of Interest 
(Figure and Figure legend courtesy of BJR|case reports: Georgios Kalarakis, Katharina 
Brehmer, Anders Svensson, Rimma Axelsson, Torkel B Brismar, Antonios Tzortzakakis. 
Combining contrast-enhanced ultrasound, CT perfusion and 99mTc-Sestamibi SPECT/CT to 
guide diagnosis in a case of solid renal tumour. BJR|case reports. September 2020) 
 
 
1.5.4 99mTc-Sestamibi SPECT/CT 
An increasing number of publications indicates the beneficial role of SPECT/CT in the 
differentiation of RO from RCC using 99mTc-Sestamibi as a radiotracer. Two recent reviews 
summarise the relevant published studies that reveal how 99mTc-Sestamibi uptake from a solid 
renal tumour indicates its possible benign nature (Fig.6g-h) and suggest modern algorithms 
for the management of 99mTc-Sestamibi positive (Sestamibi positive) renal tumours [43,44]. 
The mechanism of 99mTc-Sestamibi uptake is based on radiotracer’s sequestration in the 
mitochondria of living cells. The last-mentioned property of 99mTc-Sestamibi is used in 
oncological research imaging for tracing tumours containing an increased number of 
mitochondria such as RO and HOCT (Fig.7,8) [45]. Scintigraphy efforts have been reported 
since 1996 when Gormley et al. concluded that 99mTc-Sestamibi imaging could play a role as 
a non-invasive method in RO diagnosis [46]. In this context, Rowe et al. supported the added 
value of 99mTc-Sestamibi SPECT/CT in the differential of benign RO from malignant RCC 
[47]. The hypothesis that RO shows uptake of 99mTc-Sestamibi on a SPECT/CT examination 
was verified after demonstrating that a relative 99mTc-Sestamibi uptake ratio of 0.6 correctly 
identifies RO and HOCT versus other renal tumours with a sensitivity of 87.5% and a 
specificity of 95.2% [48]. The relative 99mTc-Sestamibi uptake ratio measuring the uptake in 
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the renal tumour and the ipsilateral non-tumoral renal parenchyma could not be correctly 
assessed on a scintigraphy image before the introduction of SPECT/CT cameras [49]. 
Advances in software with modern algorithms for image reconstruction accompanied by 
sophisticated compensation techniques for correction of photon attenuation and scattering 
have made quantitative SPECT possible like quantitative PET [50]. The aforementioned 
sensitivity and specificity values were extracted after classifying RO and HOCT as tumours 
of benign character since both tumour categories showed 99mTc-Sestamibi uptake and no 
aggressive behaviour has been documented for HOCT [51] (Fig.9). It is noteworthy though 
that the official WHO classification of renal neoplasia still considers HOCT as a malign 
entity, namely a subtype of chRCC [11]. Of note is also the fact that 50% of the examined 
chRCC, which are tumours of indolent clinical course, exhibited 99mTc-Sestamibi uptake [48]. 
 
 
Figure 7: (a) Coronal venous/nephrographic phase contrast-enhanced CT, (b) coronal 
99mTc-sestamibi SPECT, and (c) coronal 99mTc-sestamibi SPECT/CT fusion images of a large 
renal mass (white and black arrowheads) with a stellate central scar. This pathology proven 
oncocytoma demonstrates the typical pattern seen in the context of the presence of a central 
scar, with predominantly peripheral radiotracer uptake and relative photopenia in the scar.  
(Figure and Figure legend courtesy of Br J Radiol: Scott P Campbell, Antonios Tzortzakakis, 
Mehrbod S Javadi, Mattias Karlsson, Lilja B Solnes, Rimma Axelsson, Mahamad E Allaf, 
Michael A Gorin, Steven P Rowe. 99mTc-sestamibi SPECT/CT for the characterisation of 






Figure 8: (a) Sagittal arterial/corticomedullary phase contrast-enhanced CT, (b) sagittal 
99mTc-sestamibi SPECT, and (c) sagittal 99mTc-sestamibi SPECT/CT fusion images of a 
predominantly exophytic photopenic (i.e., “cold”) tumour (white and black arrowheads) with 
uptake markedly less than the adjacent normal renal parenchyma. This lesion was resected 
and was found to be a clear cell RCC.  
(Figure and Figure legend courtesy of Br J Radiol: Scott P Campbell, Antonios Tzortzakakis, 
Mehrbod S Javadi, Mattias Karlsson, Lilja B Solnes, Rimma Axelsson, Mahamad E Allaf, 
Michael A Gorin, Steven P Rowe. 99mTc-sestamibi SPECT/CT for the characterisation of 












Figure 9: (a) Axial arterial/corticomedullary phase contrast-enhanced CT, (b) axial 99mTc-
sestamibi SPECT, and (c) axial 99mTc-sestamibi SPECT/CT fusion images demonstrating a 
tumour [white arrowhead in (a)] with heterogeneous uptake. Portions of the tumour have 
radiotracer uptake similar to renal parenchyma [white arrows in (b, c)] and other portions 
are distinctly low in uptake [red arrows in (b, c)]. This is another uptake pattern that 
suggests a benign or indolent lesion, and this tumour was found to be a HOCT upon 
resection. 
(Figure and Figure legend courtesy of Br J Radiol: Scott P Campbell, Antonios Tzortzakakis, 
Mehrbod S Javadi, Mattias Karlsson, Lilja B Solnes, Rimma Axelsson, Mahamad E Allaf, 
Michael A Gorin, Steven P Rowe. 99mTc-sestamibi SPECT/CT for the characterisation of 




1.6 Histological characterisation of renal neoplasia 
The number of core needle renal biopsy increases to reduce the overtreatment of benign renal 
tumours or when metastatic disease is present, in order to choose the suitable medical 
treatment [52]. The histological analysis by defining the subtype of RCC indicates the 
metastatic potential of the renal tumour, together with the tumour size and the sex of the 
patient [8]. Apart from the RCC subtype, histology indicates the nuclear grade [53] (e.g. 
Fuhrman grading system), the invasion of nearby tissue and vessels, the presence of 
sarcomatoid features as well as the presence of lymphadenopathy [20]. An accurate 
preoperative diagnosis of renal neoplasia appears to have difficulties, not only on imaging but 
also on histology grounds. In a metanalysis from Patel et al., 25% of RO diagnoses based on 
core biopsy reclassified as chRCC or HOCT after excision [14]. In that way, core biopsy 
becomes unreliable for a definite RO diagnosis since it represents a limited sample from the 
examined tumour tissue [52]. The differential diagnostic dilemma between RO and chRCC 
exist not only for material from core biopsies but also for nephrectomy specimens, 
emphasising in that way the limitations of histopathology and immunohistochemistry [54]. 
Other histology-based tools proposed for accurate differentiation of renal neoplasia apart 
from immunohistochemistry are in situ metabolomics [55], genomic approach [56] as well as 
computed assisted morphometry [57]. The last three mentioned tools are still on a research 
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level, and they are not used in everyday clinical praxis like histopathology and 
immunohistochemistry.   
 
1.7 Treatment of renal neoplasia 
Partial or radical nephrectomy is nowadays the only curative therapies for non-metastatic 
RCC with the former exhibiting better postoperative results in localised (T1a-b) tumours [20]. 
Active surveillance [58] and thermal ablation (percutaneous radiofrequency ablation or 
cryoablation) are alternative to surgery therapeutical approaches when the patient is unfit for 
surgery or when having small renal tumours [20]. Recent research from Bianchi et al. shows 
higher recurrence-free survival for patients with non-clear RCC and tumours smaller than 
2cm when treated with partial nephrectomy or cryoablation than those treated with 
radiofrequency ablation [59]. Metastatic RCC requires systemic therapy (immunotherapy or 
targeted therapy mainly for ccRCC) whereas the effect of a cytoreductive nephrectomy is still 
under validation and ongoing research [60]. 
 
 11 
2 RESEARCH AIMS 
 
General aim 
The aim of this doctoral thesis is to explore if preoperative imaging with 99mTc-sestamibi 
SPECT/CT can have a beneficial role in the differential diagnosis of RO from RCC. To 
achieve that, our institution initiated during 2015 the MIDOR project (Molekylär Imaging för 
Differentiering av Onkocytom från Renal cancer, Drn 2015-01080) under the guidance of 
professor Rimma Axelsson. The Local Radiation Safety Committee and the Regional Ethics 
Review Board in Stockholm (Drn 2015/923-31/4) approved MIDOR study. In addition, our 
scientific group acquired written informed consent by all MIDOR project participants. 
VINNOVA financially supported MIDOR project and Hermes Medical Solutions Stockholm, 
Sweden introduced a new SUV SPECT®   software enabling that way quantitative 
measurements on the examined MIDOR material. In that way, MIDOR project brought 
together different agencies (Karolinska Institutet, Karolinska University Hospital Huddinge, 
VINNOVA and Hermes Medical Solution) under a common goal to evaluate a new hybrid 
molecular technique in the field of renal oncologic imaging.  
 
Study n.1 
The first scientific paper aimed to examine whether the visual evaluation of 99mTc-sestamibi 
uptake from the examined renal tumours undergoing SPECT/CT examination can 
differentiate RO from RCC. 
Study n.2 
The second scientific paper evaluated the intra- and interobserver agreement of quantitative 
SUV SPECT measurements of the 99mTc-sestamibi uptake from the examined MIDOR 
material. 
Study n.3 
The principal aim of the third scientific paper was to evaluate if 99mTc-Sestamibi SPECT/CT 
combined with in-situ metabolomics analysis can characterise renal tumours exhibiting 
99mTc-Sestamibi uptake.  
Study n.4 
The principal aim of the fourth paper was to investigate whether the addition of quantitative 
evaluation, namely SUV SPECT uptake from the examined MIDOR material could improve 






3 MATERIALS AND METHODS 
 
3.1 Recruitment of MIDOR participants 
The Urology Department of Karolinska University Hospital, Huddinge was responsible for 
the recruitment of patients willing to participate in the MIDOR project. The total number of 
patients included was 52. This thesis has four scientific studies based on MIDOR participants 
that included gradually between 2015-2019. Inclusions criteria were common for the four 
studies, namely T1 renal tumours, smaller than 7cm in size, with no metastatic 
manifestations. All patients discussed in the multidisciplinary urological conference of the 
Radiology Department of Karolinska University Hospital, Huddinge and decision for 
nephrectomy (partial/total) or percutaneous kidney biopsy was taken. Before surgery or 
biopsy, the patients underwent a 99mTc-Sestamibi SPECT/CT examination in the Nuclear 
Medicine Department of Karolinska University Hospital, Huddinge.  
 
3.2 Image acquisition 
The same imaging protocol applied for all MIDOR participant concerning the 99mTc-
Sestamibi SPECT/CT examination. Sixty to ninety minutes after the injection of 925 ± 25 
MBq 99mTc-Sestamibi (production and distribution: National Centre for Nuclear Research, 
Poland respectively S. Ahlén Medical Nordic AB, Stockholm, Sweden) SPECT/CT imaging 
was performed. Image acquisition took place on a Siemens Symbia T16 
(Siemens Healthcare, Erlangen, Germany) system equipped with low-energy high-resolution 
collimators. SPECT imaging was accomplished with a 128×128-pixel matrix size (zoom 
factor 1) and the acquisition of 64 projections in a step-and-shoot mode, during a 40 seconds 
time frame for each projection. CT imaging for attenuation correction and anatomical 
correlation followed the SPECT acquisition, using 130 kV tube voltage and a 5mm slice 
width. To provide proper tube current modulation with a quality reference mAs setting of 10, 
the automatic exposure control CARE Dose4D was activated. [61]. The iterative OSEM 
algorithm (6 iterations, 16 subsets) was applied for scatter correction. After the attenuation 
and collimator resolution, post-filtration was performed using a Gaussian 3D-filter (8 mm 
full-width at half-maximum).  Information about syringe activity, residual activity in the 
syringe, patient weight, time points of injection and scan start were acquired to perform the 
quantitative evaluation. The data above were specified in the reconstruction software. The 
reconstruction of SPECT and CT data acquired, performed with HERMES Hybrid Recon™ 
Oncology v.1.1B (HERMES Medical Solutions AB, Stockholm, Sweden). 99mTc-Sestamibi 
SPECT/CT examinations were visually evaluated twice by two independent readers and 
measurements of 99mTc-Sestamibi uptake in the renal tumour and the non-tumoral kidney 
parenchyma performed within a one-week interval in HERMES Hybrid Viewer PDR v2.5.  
 
3.3 Study n.1 
Twenty-four patients included in the first pilot study of this thesis. Four patients had multiple 
bilateral tumours resulting in a total of 31 kidney tumours to be evaluated. In this first 
scientific study, a visual assessment of 99mTc-Sestamibi uptake from the examined kidney 
tumours was performed blindly within a one-week period, once by a professor in nuclear 
medicine and once by a senior consultant radiologist. Our scientific group decided that any 
focal 99mTc-Sestamibi uptake from the renal tumour was considered as positive (Sestamibi 
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positive), whereas tumours with 99mTc-Sestamibi uptake lower than non-tumoral kidney 
parenchyma was considered as negative (Sestamibi negative). The results of the above-
mentioned visual assessment correlated subsequently with the clinical, histopathological 
results from the surgical specimens or the biopsy material.   
 
3.4 Study n.2 
Forty-eight kidney tumours from patients participating in the MIDOR project were included 
in the second scientific study. Standard uptake value (SUV) measurements were performed 
by freehand drawing regions of interest (ROI) at the site of the renal tumour and the 
ipsilateral non-tumoral kidney parenchyma on the axial fused SPECT/CT images as shown 
on Fig.10. Subsequently, volumes of interest (VOIs) based on the manually drawn ROIs were 
generated from the software, extracting at the same time SUVmax, SUVmean   and SUVpeak for 
the renal tumours and the non-tumoral kidney parenchyma (Fig.11). The level of agreement 
among the different SUV measurements was evaluated by calculating the intraclass 
correlation coefficient (ICC) [62].  
 
 
Figure 10: Manual drawing (A, B) in two different regions of interest (ROI), at the site of the 





Figure 11: Volumes of interest (VOIs) based on the manually drawn ROIs (A) were 
generated from the software, extracting at the same time SUVmax, SUVmean   and SUVpeak for 
the tumour on the right kidney (Fig.10) and the non-tumoral kidney parenchyma (B). 
 
3.5 Study n.3 
A complimentary approval by the Regional Ethics Review Board in Stockholm (2018/1626) 
and the Stockholm Biobank (Bbk 2082) along with a newly signed informed consent form 
were obtained before the beginning of the third scientific study. 
Tumour material from MIDOR participants was retrieved, namely haematoxylin & eosin 
(HE), as well as immunohistochemistry (IHC), slides from the archives of Clinical 
Pathology-Cytology Department Karolinska University Hospital in Huddinge. Two 
independent histopathologists reviewed the whole MIDOR material, and their diagnosis was 
utilised as the gold standard to which visual assessment 99mTc-Sestamibi SPECT/CT results 
and in-situ metabolomics data were compared. Tissue microarray analysis (TMA) of 33 
tumour samples from 28 patients included in the third scientific study to investigate their in-
situ metabolome status. Research Unit Analytical Pathology (Helmholtz Zentrum München) 
performed matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry imaging 
(MSI) analysis, as described previously by Ly et al. [63]. To validate emerging data, we used 
part of a previously published cohort, comprising 117 tumours: 59 ROs and 58 chRCCs. 
Metabolomic differences found between Sestamibi positive and Sestamibi negative chRCCs 
gave rise to an additional review from an expert urological histopathologist [64]. MALDI 
MSI data analysis, as well as image generation, was facilitated by FlexImaging v. 4.2. K-
means analysis was performed by SCiLS Lab software, followed by R-package CARRoT 
analysis to assess the highest predictive power in the differential of RO from chRCC. 
Heatmap-based clustering, s-PLSDA and volcano plots were created with MetaboAnalyst 
3.0. 
 
3.6 Study n.4 
In the fourth scientific study of MIDOR project, 58 renal tumours from 52 patients were 
included [62]. In this final assessment, two readers evaluated the MIDOR material, both 
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visually and quantitatively. To improve interobserver variation concerning the visual 
evaluation, we defined the uptake of 99mTc-Sestamibi from the examined renal tumour, as 
follows: a tumour was classified as Sestamibi-positive if the 99mTc-Sestamibi uptake was 
higher compared to ipsilateral non-tumoral renal parenchyma. If the uptake from the renal 
tumour was equal to, or lower than ipsilateral renal parenchyma, then the tumour was 
classified as Sestamibi-negative.  
Quantitative evaluations were performed by measuring SUVmean and SUVmax in the renal 
tumour and the ipsilateral non-tumoral renal parenchyma. Freehand ROIs were drawn 
manually in the CT images of the SPECT/CT examination and not on the fused image like in 
previous study 2, including the whole renal tumour. Volumes of interest (VOIs) were 
automatically generated, and SUV-parameters were noted. In this study, fixed 1cm3 VOIs 
spheres were preferred and drawn manually in regions of high 99mTc-Sestamibi uptake to 
obtain SUVmean and SUVmax values of the ipsilateral non-tumoral renal parenchyma. SUVpeak 
measurements were not included since many tumours were too small in volume 
(approximately 1cm3) to be evaluated with this parameter as by definition SUVpeak represents 
the maximum 99mTc-Sestamibi activity concentration in a 1cm3 volume within a larger VOI. 
MIDOR’s histopathological material (surgical resection specimens and/or biopsies) was re-
evaluated. Two consultant histopathologists independently reviewed HE as well as IHC slides 
of all tumours in a blinded manner. Their histopathological diagnoses were correlated with 
the results from the visual assessment of 99mTc-Sestamibi SPECT/CT examinations. A third 
histopathologist, who is an expert in renal neoplasia, was asked to blindly evaluate all 
chRCCs included in this study since in situ metabolomic differences in Sestamibi-positive 
versus Sestamibi-negative chRCCs have been found [64]. 
To evaluate the mitochondrial content of renal oncocytic tumours that appear to be positive in 
99mTc- Sestamibi examination, succinate dehydrogenase complex subunit B (SDHB) protein 
expression was used since IHC can detect SDHB protein expression. Samples from 19 
tumours (9 RO, 3 HOCTs and 7 chRCCs) previously arranged in a TMA format were utilised 
[64]. 
ICC was evaluated to assess the intra-reader reliability of the different SUV measurements in 
the renal tumour and the non-tumoral renal parenchyma. Consequently, we calculated the 
average value between the two separate measurements (SUVmax, respectively SUVmean 
SPECT/CT) from each reader per patient. This average value was used in our analysis as well 
as the ratio of the relative 99mTc- Sestamibi uptake (rate of SUVmax respectively SUVmean 
uptake from the renal tumour / SUVmax respectively SUVmean uptake from ipsilateral non-
tumoral renal parenchyma).  Receiver operating characteristic (ROC) curve analysis was used 
to exemplify and understand the trade-off in sensitivity and specificity of Sestamibi-positive 
vs Sestamibi-negative renal tumours. To demonstrate the illustration of the results in an easy 
way, each tumour category was designated with a letter, namely A-J (Fig.12).  
The SDHB score was analysed both as a categorical and numerical variable. Categorical 
SDHB (ranging from 0 to 4) was analysed with Fisher’s Exact Test, and numerical SDHB 
was analysed with Wilcoxon Sum Rank Test. 
 
 17 






4.1 Study n.1 
Sixteen out of 31 lesions underwent partial or total nephrectomy. The remaining 15 were 
biopsied—the results of the visual evaluation correlated with the clinical, 
histopathological diagnosis. According to our initial hypothesis, renal tumours that were 
categorised as Sestamibi positive were most probably RO whereas Sestamibi negative 
tumours were most probably RCC. The results of the visual evaluation are summarised in 
Table 1. Like in other similar studies HOCT were also Sestamibi positive. One pRCC 
had slightly increased 99mTc- Sestamibi uptake. 
 
Type of lesions Number of 
lesions 
Sestamibi positive Sestamibi negative 
RO 12 (39%) 11 (91,6%) 1 (8,4%) 
HOCT  3(10%) 3 (100%) 0 
Metanephric adenoma 1(3%) 0 1 (100%) 
Lymphoma 1(3%) 0 1 (100%) 
AML 1(3%) 1 (100%) 0 
ccRCC   7(23%) 0 7 (100%) 
pRCC   3(10%) 1 (33,3%) 2 (66,7%) 
ChRCC 2(6%) 0 2 (100%) 
Collision 
(chromophobe RCC – 
papillary RCC)  
1(3%) 0 1 (100%) 
Table 1: Visual evaluation of 31 renal tumours in terms of Sestamibi uptake resulting in a 
91.6% sensitivity and 94,7% specificity concerning the differentiation of RO. 
 
4.2 Study n.2 
Tables 2-4 summarises the ICC values as well as their upper and lower margins extracted 
from SUV SPECT measurements, performed by the two readers on the solid renal tumours 






As presented in Table 1a, ICC concerning the SUVmean measurements of the solid renal 
tumour (T) in the same reader varies between 95%-98%. The ICC of SUVmean measurements 
on the ipsilateral healthy renal parenchyma (N) varies between 93%-98%. 
Test-retest same 
reader ICC Lower Upper 
Reader 1 - T 0.984 0.972 0.991 
Reader 2 - T 0.954 0.920 0.974 
Reader 1 - N 0.975 0.956 0.986 
Reader 2 - N 0.932 0.883 0.961 
Table 2a: ICC for repeated measurements of SUVmean by the same reader.  
T: renal tumour, N: non-tumoral renal parenchyma 
 
Table 2b exhibits that ICC between readers concerning SUVmean measurements of the renal 
tumours varies between 86%-89%. The ICC of SUVmean measurements on the ipsilateral 
healthy renal parenchyma between readers was found to be 73%.  
Between readers ICC Lower Upper 
First measurement - T 0.890 0.814 0.936 
First measurement - N 0.732 0.530 0.848 
Second measurement - T 0.858 0.762 0.917 
Second measurement - N 0.734 0.560 0.843 
Table 2b: ICC for repeated measurements of SUVmean between readers.  
 
SUVpeak 
Tables 3a and 3b show ICC values for SUVpeak measurements by the same reader and 
between readers, respectively. 
Test-retest same 
reader ICC Lower Upper 
Reader 1 - T 0.989 0.980 0.994 
Reader 2 - T 0.969 0.946 0.982 
Reader 1 - N 0.982 0.968 0.989 
Reader 2 - N 0.932 0.884 0.961 




Between readers ICC Lower Upper 
First measurement - T 0.887 0.809 0.934 
First measurement - N 0.705 0.526 0.823 
Second measurement - T 0.915 0.856 0.951 
Second measurement - N 0.656 0.447 0.794 
Table 3b: ICC for repeated measurements of SUVpeak between readers. 
 
SUVmax 
ICC concerning the SUVmax measurements of solid renal tumours in the same reader varies 
between 97%-99%. The ICC of SUVmax measurements on the ipsilateral healthy renal 
parenchyma varies between 92%-98% (Table 4a). 
Test-retest same 
reader ICC Lower Upper 
Reader 1 - T 0.989 0.981 0.994 
Reader 2 - T 0.965 0.939 0.980 
Reader 1 - N 0.983 0.970 0.990 
Reader 2 - N 0.921 0.865 0.954 
Table 4a: ICC for repeated measurements of SUVmax by the same reader.  
 
ICC between readers concerning SUVmax measurements of the renal tumours varies between 
87%-89%. The ICC of SUVmax measurements on the ipsilateral healthy renal parenchyma 
between readers was 72%-73% (Table 4b). 
Between readers ICC Lower Upper 
First measurement - T 0.866 0.775 0.922 
First measurement - N 0.715 0.518 0.835 
Second measurement - T 0.890 0.812 0.936 
Second measurement - N 0.729 0.524 0.847 
Table 4b: ICC for repeated measurements of SUVmax between readers.  
 
4.3 Study n.3 
The results of the visual assessment of renal tumours examined with 99mTc- Sestamibi 
SPECT/CT in the third scientific study are presented in Table 5. Of note is that the single 
pRCC exhibiting slight 99mTc- Sestamibi uptake in the first scientific study was reclassified as 
chRCC upon re-evaluation on histopathological grounds. 
 
 22 
Tumour type No. of renal 
tumours 
99mTc-Sestamibi 
positive, n (%) 
99mTc-Sestamibi 
negative, n (%) 
RO 9 7 (78%) 2 (22%) 
HOCT 3 3 (100%) 0 
chRCC 7 3 (43%) 4 (57%) 
ccRCC 6 0 6 (100%) 
pRCC (type 1) 8 0 8 (100%) 
Table 5. Visual assessment of 33 renal tumours examined with 99mTc- Sestamibi SPECT/CT 
included in the third scientific study. 
 
A discriminatory metabolomic signature for positive on 99mTc-Sestamibi SPECT/CT Birt-
Hogg-Dubè (BHD)-associated HOCT vs other renal oncocytic tumours was identified. 
Evident metabolomic differences found between 99mTc-Sestamibi positive and negative 
chRCCs that prompted an additional expert review; two of three 99mTc-Sestamibi positive 
chRCCs were reclassified as LOT, which is an emerging RCC entity (Fig.13). Metabolomic 
differences were found between distal-derived tumours (i.e., chRCC) from those of proximal 







Figure 13: Metabolomic Data Analysis Segregates 99mTc-Sestamibi SPECT/CT positive 
BHD-associated HOCTs and distinguishes SPECT/CT positive LOTs from classic chRCCs. 
(A) Unsupervised clustering analysis based on discriminative metabolites (n=460) depicting 
a clear separation between 99mTc-Sestamibi SPECT/CT positive BHD-associated HOCTs vs 
other 99mTc-Sestamibi SPECT/CT negative renal oncocytic neoplasms; (B) Heatmap of top 
420 m/z values highlights different m/z expression patterns in SPECT/CT photophilic chRCCs 
versus photopenic counterparts; (C) These in situ metabolomic differences prompted a 
pathologic evaluation of all chRCCs: Histopathological features of three 99mTc-Sestamibi 
SPECT/CT positive  chRCCs (cases No 41, 31 and 39; top to bottom) which were amended to 
LOTs (cases No 41 & 31) and eosinophilic chRCC (case No 39) upon expert review. A 99mTc-
Sestamibi SPECT/CT negative classic chRCC (case No 51) is also included in the panel 
(bottom); (D) Histological features and hybrid molecular imaging (scintigraphic, SPECT/CT 
and CT study) of three 99mTc-Sestamibi SPECT/CT positive cases: HOCT (case No 8: axial 
view of 13 mm tumour on the dorsal aspect of right kidney exhibiting 99mTc-Sestamibi 
uptake), RO (case No 14: coronal view of 60 mm tumour with a necrotic component on the 
upper pole of left kidney exhibiting 99mTc-Sestamibi uptake), and LOT (case No 41: coronal 
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view of 28 mm tumour on the lower pole of left kidney exhibiting 99mTc-Sestamibi uptake), as 
well as 99mTc-Sestamibi SPECT/CT negative classic chRCC (case No 51: coronal view of 64 
mm tumour on the medial aspect of the lower pole of left kidney without 99mTc-Sestamibi 
uptake; top to bottom).  
(Figure and Figure legend courtesy of Papathomas T, Tzortzakakis A, Sun N, Erlmeier F, 
Bozoky B, Kokaraki G, et al. In Situ Metabolomics Expands the Spectrum of Renal Tumours 
Positive on 99m Tc-sestamibi Single Photon Emission Computed Tomography / Computed 
Tomography Examination. Eur Urol Open Sci. European Association of Urology.; 
2020;22:88–96) 
 
4.4 Study n.4 
Five renal tumours reclassified upon re-evaluation by consensus: 4 RO were reclassified as 
chRCC and HOCT (2 cases each), while one papillary RCC reclassified as chRCC. Another 
renal mass previously characterised as HOCT corresponded to healthy renal parenchyma and 
thus excluded from further analysis reducing the total number of tumours to 57.  
Accordingly, the final diagnoses were established as follows: 13 ccRCCs, 11 chRCCs, 11 RO 
(one with adjacent) papillary adenoma, 9 pRCCs, 5 HOCTs, 4 ccpRCCs (one with adjacent 
papillary adenoma), 1 “collision tumour” comprising chromophobe RCC with adjacent 
pRCC, 1 B cell non-Hodgkin’s (follicular) lymphoma, 1 metanephric adenoma and 1 AML. 
Agreement between the readers concerning the visual evaluation of 99mTc-Sestamibi uptake 
was observed in 51 out of 57 (89.5%) solid renal tumours. In 6 (10.5%) cases, the two readers 
were in disagreement. A third reader with a nuclear medicine background was introduced, 
and all three readers independently performed a blind re-evaluation of those six cases: a 
complete agreement was achieved between the two readers with a nuclear medicine 















Histological types of 
renal tumours 
Number of renal 
tumours 
99mTc- Sestamibi 
positive, n (%) 
99mTc- Sestamibi 
negative, n (%) 
RO 11 9 (82%) 2 (18%) 
HOCT 5 5 (100%) 0 
chRCC 11 6 (55%) 5 (45%) 
ccRCC 13 0 13 (100%) 
pRCC 9 0 9 (100%) 
ccpRCC 4 0 4 (100%) 
Collision RCC 1 0 1 (100%) 
B-cell Lymphoma 1 0 1 (100%) 
Metanephric 
adenoma 
1 0 1 (100%) 
AML 1 0 1 (100%) 
Table 6: Visual evaluation of 99mTc-Sestamibi uptake on 57 solid renal tumours resulting in 
82% sensitivity and 76% specificity concerning the differentiation of RO. 
 
Similar to our previously scientific study 2, the ICC for SUVmax and SUVmean measurements 
between the two readers showed a high agreement of 88% and 94%, respectively. Likewise, 
the ICC between the readers, when measuring SUV parameters in the ipsilateral non-tumoral 
renal parenchyma showed moderate agreement. 
Statistical analysis of the quantitative evaluation revealed significant results (p-value less than 
0.001) in SUVmax, and SUVmean SPECT/CT measurements performed on renal tumours and 
the non-tumoral renal parenchyma. ROC curve analyses based on the ratio of the relative 
99mTc-Sestamibi uptake were performed by sub-clustering RO as a SPECT/CT positive 
subgroup (subgroup A). At the same time, all remaining tumour types were considered a 
SPECT/CT negative subgroup. Cut-off values for the characterisation of RO as Sestamibi-
positive vs all the rest tumours subgroups were obtained. The ratio of relative 99mTc-
Sestamibi uptake based on SUVmax measurements of the tumour (T) vs non-tumoral renal 
parenchyma (N) demonstrated the best performance under the curve (0.787) (Fig. 14) 





Figure 14: Ratio of relative 99mTc-Sestamibi uptake based on SUVmax measurements on the 
renal tumour (T) and the non-tumoral renal parenchyma (N). Quantitative evaluation of 
SUVmax measurements of 99mTc-Sestamibi uptake on 57 solid renal tumours resulted in 64% 
sensitivity and 83% specificity in detecting RO. 
 
One expert urological histopathologist re-evaluated all chRCCs: five renal Sestamibi- 
negative tumours were classified as 4 chRCCs classic type and 1 as an eosinophilic variant of 
chRCC. Six Sestamibi-positive tumours were reclassified as 3 LOTs, 2 as eosinophilic 
variants of chRCC and 1 chRCC classic type. However, all these tumours were included in 
the chRCC subgroup given that LOT represents an emerging renal tumour entity that has 
been recently proposed, which awaits formal acceptance and potential inclusion in the WHO 
classification [65]. 
The median SDHB score in the Sestamibi positive group was 4 vs 3 in the negative group, 
with the most common value being 4 in the former and 3 in the latter. A trend of higher 
SDHB values in the positive group was found compared to the negative group (p=0.183 vs 
p=0.071). A linear-by-linear association test, to keep SDHB as a categorical variable taking 
the order of values into account, suggested a significant trend (p=0.038). There was no 
statistically significant difference in the SDHB immune expression patterns between the 







Our data confirmed the hypothesis that RO show 99mTc-Sestamibi uptake in SPECT/CT 
examination resulting in a high sensitivity of nearly 92%, which was in accordance with other 
published studies at that time [47,48]. The three Sestamibi positive HOCTs was another 
common finding with the studies mentioned above from John Hopkins scientific group [48]. 
HOCT constitutes a subtype of chRCC without any evidence of metastatic potential although 
no publications with follow-ups longer than ten years exist [66]. HOCT is an emerging renal 
entity which is distinct from RO and chRCC [11]. The presence of false-positive results 
indicated the eventual need for quantitative tools in addition to visual assessment for more 
accurate characterisation of renal neoplasia. Hermes Medical Solutions Stockholm, Sweden 
introduced SUV SPECT®   software that could enable quantitative evaluation of the examined 
MIDOR material leading our group to continue with the second scientific study to validate 
the measurements performed by the software mentioned above. 
 
Study n.2 
SUV SPECT®   software from Hermes Medical Solutions enables SUV SPECT measurements 
on the examined renal tumours resulting in ICC between readers to be around 85%-90%. 
That means that 85%-90% of the observed variability is mostly due to actual variability 
among the examined tumours, and only about 10%-15% is due to variability between readers. 
A 10%-15% variability in the measurements between readers is a percentage of measurement 
error which is acceptable in everyday clinical praxis. The intrinsic limitations of SPECT/CT 
examination, the difficulty in drawing the ROIs manually on the fused SPECT/CT images 
especially in small-sized renal tumours, the challenges in obtaining SUVpeak values mainly in 
small-sized tumours and the heterogenicity of larger renal tumours were the main limitations 
revealed in this second scientific study. The strong agreement among the different SUV 
measurements performed on MIDOR material encouraged our group to utilize quantitative 
tools besides visual assessment of 99mTc-Sestamibi uptake from the examined kidney tumours 
and non-tumoral kidney parenchyma.  
 
Study n.3 
In this third scientific study, we suggested an in-situ metabolomic analysis of renal tumours 
previously examined with 99mTc-Sestamibi SPECT/CT examination. This resulted in the 
expansion of 99mTc-Sestamibi positive renal tumours encompassing RO, HOCT, LOT and 
chRCC, supporting in that way combined diagnostics that utilise molecular imaging and 
histometabolomic profiling. Two 99mTc-Sestamibi positive cases initially considered chRCC 
(eosinophilic type) clustered together and separately from the negative classic chRCCs; both 
were reclassified as LOTs upon expert review. Three BHD-associated HOCT cases also 
exhibited distinct metabolomic profile, further reinforcing the concept that HOCT may 
represent a unique renal entity and not a chRCC subtype/variant, according to the current 
WHO classification. The principal limitation of this study was the small number of cases 
investigated using both 99mTc-Sestamibi SPECT/CT and MALDI-MSI with a variable 
representation of tumour entities. Nevertheless, the diverse metabolic profiles and behaviour 
of chRCC which may appear both Sestamibi positive and Sestamibi negative on 99mTc-
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Sestamibi SPECT/CT examination, generated a closer look to this indolent RCC subgroup 
and the description of an emerging RCC entity namely LOT (Fig. 15). 
 
 
Figure 15: One Sestamibi-negative and one Sestamibi-positive chRCC. 
First row, a-e: (case 42) SPECT axial image (a) indicates the absence of radioisotope in a 
classic chromophobe RCC located at the dorsal aspect of the left kidney (indicated by arrow). 
Fused axial SPECT/CT images (b), white arrow indicates the tumour. Preoperative axial 
CECT image (c) in the venous phase, white arrow indicates the tumour. Histological sections 
of the tumour characterised as a chRCC (d-e) upon expert review. 
Second row, f-j: (case 31) SPECT coronal image (f) indicates focal radioisotope uptake in a 
chromophobe RCC located at the upper pole of the left kidney (indicated by arrow). Fused 
axial SPECT/CT images (g), white arrow indicates the tumour. Preoperative axial CECT 
image (h) in the venous phase (white arrow indicates the tumour). Histological sections of the 




Quantitative evaluation with SUV SPECT measurements did not improve the performance of 
99mTc-Sestamibi SPECT/CT examination in differentiating RO from RCC compared to visual 
evaluation. All HOCTs and approximately half of the chRCC cases were classified as 
Sestamibi-positive, raising the question of clinical importance of how often tumours with an 
indolent clinical course might be misclassified (Fig.16). This finding could be eventually 
incorporated into modern active surveillance programs to reduce the overtreatment of benign 
renal tumours. In this study, a semi-quantitative immunohistochemical analysis of the 
mitochondrial content did not yield any significant differences between Sestamibi-positive 
and Sestamibi-negative renal tumour subsets, possibly attributed either to the functional 
status of the mitochondria or to the intra-tumoral heterogeneity, given the limited tumour 








Figure 16: A RO and a HOCT, both positive on 99mTc-Sestamibi SPECT/CT. 
First row, a-e: (case n.9) The scintigraphy study (a) displays an axial view of focal 
radioisotope uptake in the anterior aspect of the left kidney (indicated by arrow). Anatomic 
correlation of the previous uptake (c) in the CT study, axial view-venous phase. The axial 
SPECT/CT fusion image (b) with 99mTc-Sestamibi uptake in the same solid renal neoplasm 
(12mm in maximum diameter) of the left kidney. This was subsequently diagnosed as HOCT 
on histopathology (d-e). 
Second row, f-j: (case n.13) The scintigraphy study (f) displays a coronal view of focal 
radioisotope uptake in the upper pole of the left kidney (indicated by arrow). Anatomic 
correlation of the previous uptake (h) in the CT study, axial view-venous phase. The axial 
SPECT/CT fusion image (g) with 99mTc-Sestamibi uptake in the same solid renal neoplasm 
(69mm in maximum diameter) of the left kidney. This was subsequently diagnosed as RO on 










The visual interpretation of 99mTc-Sestamibi SPECT/CT shows clear benefits as a new 
diagnostic tool in the characterisation of renal neoplasia. Renal tumours without uptake of 
99mTc-Sestamibi on SPECT/CT have most probably a malignant character, whereas renal 
tumours with 99mTc-Sestamibi uptake are likely benign. 
 
Study n.2 
SUV SPECT measurements on the renal tumours of MIDOR material performed in HERMES 
Hybrid Viewer PDR v2.5 showed high ICC values around 90%. Those high ICC values 
indicate a strong agreement among the different SUV measurements for patients with renal 
tumours examined with 99mTc-Sestamibi SPECT/CT. 
 
Study n.3 
The third scientific study by supporting the feasibility of an integrated in-situ metabolomic 
profiling for the characterisation of renal tumours provides novel molecular insights into 
renal neoplasia. Our research suggests that renal tumours positive on 99mTc-Sestamibi 
SPECT/CT should be biopsied and analysed in an integrated fashion to guide further clinical 
decisions. New emerging renal entities like LOTs appear to have different metabolic 




Quantitative evaluation with SUV SPECT measurements did not improve the performance of 
visual evaluation on a 99mTc-Sestamibi SPECT/CT examination in characterising RO and 
differentiating this benign renal tumour from RCC. Visual evaluation of 99mTc-Sestamibi 
SPECT/CT identifies a larger Sestamibi-positive tumour group containing RO, HOCT and 
the majority of chRCCs.  Sestamibi-negative renal tumours should be considered for surgery. 
On the other hand, Sestamibi-positive renal tumours could be suited for biopsy or follow up 
according to modern surveillance protocols. Emerging new renal tumour entities such as LOT 






7 POINTS OF PERSPECTIVE 
 
Research projects like MIDOR is a clear example of how Academic structure, Clinical praxis 
and Private sectors can cooperate to achieve novel, beneficial results for the health care 
system and subsequently the society. Similar future efforts should be promoted and 
encouraged when clear rules and roles for the different counterparts exist. 
John Hopkins’s scientific group and Karolinska’s MIDOR study were the first to demonstrate 
the beneficial role of 99mTc-Sestamibi SPECT/CT in the characterisation of renal neoplasia 
and how hybrid imaging could contribute in the reduction of overtreating benign renal 
tumours [43,44]. During the past year more scientific groups have published similar results 
[67–69] underlining the increasing interest in this field of renal oncologic imaging. 
In accordance with the studies mentioned above, our scientific team concluded that 99mTc-
Sestamibi SPECT/CT points out a larger group of renal tumours that show 99mTc-Sestamibi 
uptake. This group contains renal tumours of indolent clinical course like RO, HOCT and 
chRCC. At the same time, 99mTc-Sestamibi SPECT/CT followed by in situ metabolomic 
analysis added valuable evidence in an emerging renal tumour subcategory which is 
metabolically unique, namely LOT [64] since we observed different metabolic signatures 
between Sestamibi positive and Sestamibi negative chRCCs. 
Nowadays, a large number of publications indicate that ROs are Sestamibi positive. Patients 
with Sestamibi positive renal tumours could avoid or postpone surgical treatment. Instead, a 
renal biopsy could be preferred as well as a longer follow up period to track the dynamics of 
the examined renal neoplasia.  
Further metabolomic analyses in bigger tumour samples could contribute to distinct 
metabolic signatures, increasing in that way the confidence of a renal biopsy. For example, 
our study indicated a unique metabolic profile for HOCT from a single BHD patient. It would 
be interesting to know if that is the general case for HOCT. LOT is another emerging renal 
tumour entity that should be examined and further characterised in clinical settings to 
ascertain its assumed indolent character.  
A recent cost-effectiveness analysis [70] indicates that modern cancer track algorithms in 
urologic oncology should include 99mTc-Sestamibi SPECT/CT examination since there are 
clear financial and diagnostic benefits from its use. The knowledge mentioned above that 
99mTc-Sestamibi SPECT/CT brings in the characterisation of renal neoplasia followed by a 
confirmatory renal biopsy can reduce not only the overtreatment of benign renal tumours but 
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